Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This study is for patients with cancer of the prostate gland that has metastasized or spread
outside the prostate to other parts of the body. Patients have already been treated with a
drug called docetaxel or Taxotere® (with or without the addition of a steroid called
prednisone) some time in the recent past. They either did not respond to this therapy or
responded to this therapy, but now the cancer is progressing (growing larger or has spread to
other areas of the body).
Custirsen (OGX-011) is an experimental drug that has been shown to increase the effectiveness
of chemotherapy in several kinds of tumors, including prostate cancer.
Both docetaxel and mitoxantrone have anticancer activity in prostate and are approved by
Health Canada and the Food and Drug Administration for the treatment of patients with
prostate cancer.